Authors' Reply: Of End Points and Context of Use: A Reasonable Silver Lining for Urinary Chemokines Monitoring
- PMID: 37782547
- PMCID: PMC10561820
- DOI: 10.1681/ASN.0000000000000205
Authors' Reply: Of End Points and Context of Use: A Reasonable Silver Lining for Urinary Chemokines Monitoring
Conflict of interest statement
P. Hirt-Minkowski reports Advisory or Leadership Role: Alexion, AstraZeneca, and Novartis. All remaining authors have nothing to disclose.
Comment on
-
Randomized Trial to Assess the Clinical Utility of Renal Allograft Monitoring by Urine CXCL10 Chemokine.J Am Soc Nephrol. 2023 Aug 1;34(8):1456-1469. doi: 10.1681/ASN.0000000000000160. Epub 2023 May 25. J Am Soc Nephrol. 2023. PMID: 37228005 Free PMC article. Clinical Trial.
-
Of End Points and Context of Use: A Reasonable Silver Lining for Urinary Chemokines Monitoring.J Am Soc Nephrol. 2023 Oct 1;34(10):1765-1766. doi: 10.1681/ASN.0000000000000206. Epub 2023 Aug 18. J Am Soc Nephrol. 2023. PMID: 37782546 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources